Search Results

Early assays prevent late failure  — modern in vitro tools dramatically reduce attrition . initiative—clear guidance on career paths, choosing research topics, switching fields, and learning from both failures

Even compounds with pristine target profiles can fail in vivo due to poor absorption, limited tissue In the late 20th century, nearly half of investigational drugs failed due to inadequate PK. PK errors no longer dominate failure statistics, but fundamental blind spots still derail programs Kenakin shows that programs fail when these questions are skipped, deferred, or answered implicitly instead Even perfect receptor pharmacology fails if target-site exposure is insufficient or transient .

When they do not, it starts to fail quietly. The team is talented, but momentum starts leaking. 👉 Early-stage biotech hiring fails at this point,

Why Scientific Isolation Is Dangerous and Expensive This pattern rarely causes a single catastrophic failure

In this session, you’ll gain: Why saturation and displacement assays fail when protein stoichiometry

better questions in science requires accepting that uncertainty is part of the process, not a personal failing

But what looks solid internally often fails to signal true readiness from the FDA’s perspective . 👉

sense of fun, the kind of scientific joy that makes late-night imaging sessions feel lighter and big failures

Most biotech pitches don’t fail because the science is weak. They fail because the story is unclear. 👉 A confusing pitch doesn’t just slow down progress.

Some worked in one tissue but failed in another. Some detected off-targets.

Some of the most promising biotech teams aren’t failing; they’re just stuck.

Yet, any pharmacologist who’s pushed beyond textbook theory knows: biology rarely plays fair. These deviations aren’t failures—they’re clues. In Kenakin's words, “Every slope, every curvature, every failure to fit—those are the whispers of the

Michelle was part of a cohort that joined as postgrads in shared facilities, pooling reagents, ideas, and failures

When technology reduced the cost of failure, scientists could push boundaries faster.

The lab has witnessed both spectacular accuracy and puzzling failures.

A well-behaved molecule in a dish can fail spectacularly in vivo, leaving teams with years of sunk costs

cardiomyocyte-specific Adhesion G Protein Coupled Receptor G1 (ADGRG1/GPR56) promotes pressure overload-induced heart failure

Good molecules can fail quietly at this stage —not because they’re weak, but because they’re too strong When they’re ignored, they become sources of silent failure : under-penetration, persistent off-target

, he lays out the mindset that helped shape products used across biotech and academia—and why play, failure They think too narrowly, focus too early, and equate unexpected results with failure. “You can try, try, try—and fail, fail, fail,” Eric says. But those failures are where new paths emerge, often leading to transformative tools like the IP1 assay Eric Trinquet Built to Fail, Built to Win: Inside the IP1 Assay Origin Story The IP-One assay didn’t

From failing fast to embracing serendipity, Eric shares the mindset (and messy origin stories) that shaped

Most drugs don’t fail at the receptor level—they fail before they even reach it. In every lab, candidates fail not because they lack potency at a receptor, but because they stumble at Even the most elegant GPCR ligand can fail if it never reaches its receptor. potency under high substrate conditions, such as ATP-rich cancer cells, where orthosteric inhibitors fail

But behind every “new” assay is a decade of design, failure, and rethinking.

Every GPCR assay that makes it to market carries years of failures, late-night ideas, risky bets, and Built to Fail, Built to Win: The IP One Gamble After the success of their cAMP assay, Trinquet’s team Classic pH probes failed in plate readers—too noisy, too dim. pHSense rewrote that rule, enabling high-throughput You’ll fail 90% of the time.

But some leak current, like a switch glowing faintly in the dark. Model patient-like pathophysiological states (e.g., reduced receptor expression in heart failure).

But here’s the truth: too many programs still fail because early decisions were built on shaky mechanistic Months of wasted resources, failed translation, and opportunity loss.

Terry's Corner – Designing Drugs That Anticipate Physiological Pushback Most GPCR programs don’t fail Avoid compensatory misreads:  Renin inhibition drops BP in normals, but not in heart failure—because

inhibitor that lowers blood pressure in healthy volunteers might not drop blood pressure at all in heart failure bradycardia that blunts its heart rate liability—making it a better inotrope than isoproterenol in heart failure Your molecule isn’t failing—your model might be too simple.

Avoid expensive mirages:  Spot when “good” equilibrium curves mask time-dependent binding that will fail

A career pivot is not a failure—it’s a refined strategy. Catherine's decision to defer pharmacy school was a leap of faith that opened new doors.

reshape how you evaluate and advance lead compounds, potentially saving your team from costly late-stage failures Are your promising in vitro results failing to translate into real-world clinical success? Dr. Threat Avoided:  Prevent costly late-stage failures by incorporating kinetic modeling early in your pipeline